Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Longeveron Inc. LGVN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
56/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$10.00
+792.9%

Longeveron Inc. (LGVN) is a Biotechnology company in the Healthcare sector, currently trading at $1.12. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is LGVN = $10 (+792.9% upside).

Valuation: LGVN trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25).

Financials: revenue is $1M, +48.5%/yr average growth. Net income is $23M (loss), growing at -8.6%/yr. Net profit margin is -1893.6% (negative). Gross margin is 67% (+26.3 pp trend).

Balance sheet: total debt is $824,000 against $6M equity (Debt-to-Equity (D/E) ratio 0.15, conservative). Current ratio is 1.33 (adequate). Debt-to-assets is 8%. Total assets: $10M.

Analyst outlook: 4 / 4 analysts rate LGVN as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$10.00
▲ 792.86% Upside
Average Price Target
The 12-month price target for Longeveron Inc. is $10.00.

LGVN SharesGrow Score Overview

66/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LGVN

✓
VALUE Pass
100/100
LGVN trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25). Forward PEG -1.39 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $10, implying +792.9% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
LGVN: +48.5%/yr revenue is, -8.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet LGVN: Debt-to-Equity (D/E) ratio 0.15 (conservative), Current ratio is 1.33 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
LGVN: Gross margin is 67% (+26.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate LGVN as buy (100%). Analyst consensus target is $10 (+792.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
LGVN: Net profit margin is -1893.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.475-1.83
Volume838.19K
Avg Volume (30D)5.7M
Market Cap$26.1M
Beta (1Y)-0.19
Share Statistics
EPS (TTM)-1.29
Shares Outstanding$17.58M
IPO Date2021-02-12
Employees25
CEOStephen H. Willard
Financial Highlights & Ratios
Revenue (TTM)$1.2M
Gross Profit$803K
EBITDA$-22.06M
Net Income$-22.7M
Operating Income$-23.29M
Total Cash$4.66M
Total Debt$824K
Net Debt$-3.84M
Total Assets$10.26M
Price / Earnings (P/E)-0.9
Price / Sales (P/S)21.77
Analyst Forecast
1Y Price Target$10.00
Target High$10.00
Target Low$10.00
Upside+792.9%
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS54303L2034

Price Chart

Track all markets on TradingView
LGVN
Longeveron Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.48 52WK RANGE 1.83

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 KROS
KROS
Keros Therapeutics, Inc.
$11.71
+1.39%
 FBRX
FBRX
Forte Biosciences, Inc.
$31.28
-3.52%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 SRZN
SRZN
Surrozen, Inc.
$32.02
+0.53%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.89
+4.90%
 KZR
KZR
Kezar Life Sciences, Inc.
$7.38
+0.27%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message